TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01963806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT
Description: The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-supplemented iCBT
Description: The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist support
Description: The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active waiting list
Description: Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
Study: NCT01733953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (Placebo)
Description: 6-Months of placebo (sugar) pill; oral, once daily
Study: NCT03972917

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasonographic examination
Description: Evaluation of endometrial thickness; myoma size and volume
Study: NCT03134807

Intervention type: OTHER
Intervention: Observation prospective
Description: No intervention
Study: NCT06109740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lactobacillus GG
Description: probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: lactobacillus GG
Description: probiotic
Study: NCT00674297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin 40 mg daily for 3 months
Study: NCT02512952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by Open flap debridement (OFD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
Study: NCT03243799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Description: Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
Study: NCT02512952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Titanium Platelet rich fibrin (TPRF)
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
Study: NCT03113786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLARIX™100
Description: CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
Study: NCT04572035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Coaching
Description: behaviour change strategies (i.e., action planning, implementation intentions, relapse prevention, and goal setting)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion psychoeducation
Description: self-compassion strategies (i.e., mindfulness, self-directed kindness meditations, and writing tasks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise program either delivered in a laboratory setting or via Zoom

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise program either delivered in a laboratory setting or via Zoom

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic exercise program either delivered in a laboratory setting or via Zoom
Study: NCT00141921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
Study: NCT02337582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opportunistic Breast cancer screening
Description: Opportunistic breast screening offered to women attending clinics for non-breast health issues

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
Study: NCT01750437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1885L(Revaprazan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1885L(Revaprazan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1885L(Revaprazan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1885L(Revaprazan)
Study: NCT02658461

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
Study: NCT01750437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT00693264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hoodia Gordonii
Description: 750 mg capsule will be taken one time

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to be taken one time
Study: NCT00022477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Study: NCT03797053

Intervention type: PROCEDURE
Intervention: Biological sample
Description: Biological sample performed :~* before treatment~* 1 months after the beginning of treatment~* every tumoral assessment
Study: NCT00989599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compress of Chamomilla recutita infusion
Description: Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
Study: NCT03113786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLARIX CORD 1K
Description: CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues \& Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
Study: NCT00377416

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2-CB-hAAT Gene Vector
Description: Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
Study: NCT04318821

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture is a non-invasive therapy that involves stimulation of traditional acupoints with low-intensity, non-thermal laser irradiation.
Study: NCT00989599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: compress of lukewarm water
Description: Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
Study: NCT00991614

Intervention type: DEVICE
Intervention: EVOLUTION® Duodenal Stent
Description: EVOLUTION® Duodenal Stent
Study: NCT01254305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
Study: NCT00382148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: SC repeating dose
Study: NCT02048904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 pill/day for 3 months
Study: NCT02089685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN-2b
Description: Subcutaneous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: IV infusion
Study: NCT05287061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Psychological Program (MPP)
Description: Patients will receive health pills during hospital admission. This intervention will be brief for individual application, but without specific content for each person, protocolized in its content and tools, and with a cognitive-behavioral orientation. Its therapeutic objective is to provide the patient with immediate control strategies for negative emotions and some pattern of active and positive coping. Two months after hospital discharge, the patients will also receive a multicomponent psychological program of a group nature. Based on motivational interviewing and positive psychology, with two blocks: emotions and consolidation of intentions. Two individual sessions will be carried out at the beginning to be able to do individual orientation, plan the intervention protocol, determine the objectives, the group intervention, and the specific action packages that the patient will receive.
Study: NCT01118312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate monohydrate
Description: Intranasal mometasone, 1 spray (age \< 12 yr) or 2 sprays (age \>= 12 yrs) each nostril once a day for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo spray
Study: NCT03067818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unaffected Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation to unaffected hemisphere site prior to practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Affected Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation to affected hemisphere site prior to practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Transcranial Magnetic Stimulation
Description: Non-invasive brain stimulation to control site prior to practice
Study: NCT00609960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: clowns present
Description: clowns present during the proccess of induction of anesthesia
Study: NCT06071611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Oxygen-Ozone (O2-O3)
Description: Oxygen-Ozone (O2-O3) treatment by rectal insufflations for 5 weeks (3 sessions for week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Oxygen (O2)
Description: Oxygen (O2) treatment by rectal insufflations for 5 weeks (3 sessions for week).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo (Air)
Description: Air treatment by rectal insufflations for 5 weeks (3 sessions for week).
Study: NCT04233125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Decompression
Description: Core Decompression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Core Decompression
Description: Core Decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PMMA augmentation
Description: Polymethylmethacrylate (PMMA) augmentation
Study: NCT04574843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of MMA
Description: embolization of MMA with one of following liquid embolic agents (Onyx-Squid-Phil)
Study: NCT01833871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three dimensional Power Doppler to the myometrial mass
Description: Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine artery Doppler
Description: uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
Study: NCT04295590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequency comparison
Description: One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Frequency comparison
Description: One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to high-frequency low-intensity (5 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity comparison
Description: One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensity comparison
Description: One leg assigned to low-frequency low-intensity (3 days per week of 11 x 1 min @ 73% peak work rate interspersed with 1-minute periods of active recovery). The other leg assigned to low-frequency high-intensity (3 days per week of 8 x 1 min @ 100% peak work rate interspersed with 1-minute periods of active recovery).
Study: NCT00997971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modilac Rose 1
Description: Infant formula used for non-breastfed children
Study: NCT02874911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General training
Description: Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
Study: NCT01288768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroscopy
Description: Knee arthroscopy within 4 weeks.
Study: NCT01250821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menopur
Description: The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day.
Study: NCT00706732

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AVX502
Description: 2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and T=4 weeks via the IM route

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo given at T=0 and T=4 weeks via the SC route
Study: NCT00104871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Administered IV at the dose of 1.3 mg/m\^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
Study: NCT05405829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
Study: NCT04626622

Intervention type: DRUG
Intervention: Kagocel
Description: Investigators could prescribe other drugs in frame of routine clinical practice

Intervention type: DRUG
Intervention: No one
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Study: NCT00903084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet
Study: NCT00316875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: 1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule